AU2021345531B2 - Solid forms of a CDK4 inhibitor - Google Patents
Solid forms of a CDK4 inhibitor Download PDFInfo
- Publication number
- AU2021345531B2 AU2021345531B2 AU2021345531A AU2021345531A AU2021345531B2 AU 2021345531 B2 AU2021345531 B2 AU 2021345531B2 AU 2021345531 A AU2021345531 A AU 2021345531A AU 2021345531 A AU2021345531 A AU 2021345531A AU 2021345531 B2 AU2021345531 B2 AU 2021345531B2
- Authority
- AU
- Australia
- Prior art keywords
- ppm
- cancer
- values
- crystalline form
- solid state
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US63/078,636 | 2020-09-15 | ||
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| US63/240,268 | 2021-09-02 | ||
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021345531A1 AU2021345531A1 (en) | 2023-04-20 |
| AU2021345531B2 true AU2021345531B2 (en) | 2024-02-29 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021345531A Active AU2021345531B2 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a CDK4 inhibitor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230357211A1 (enExample) |
| EP (2) | EP4214202B1 (enExample) |
| JP (2) | JP7260606B2 (enExample) |
| KR (1) | KR20230069983A (enExample) |
| CN (1) | CN116507620B (enExample) |
| AU (1) | AU2021345531B2 (enExample) |
| CA (1) | CA3195063A1 (enExample) |
| DK (1) | DK4214202T3 (enExample) |
| ES (1) | ES3022913T3 (enExample) |
| FI (1) | FI4214202T3 (enExample) |
| HU (1) | HUE070846T2 (enExample) |
| MX (1) | MX2023003054A (enExample) |
| PL (1) | PL4214202T3 (enExample) |
| PT (1) | PT4214202T (enExample) |
| SI (1) | SI4214202T1 (enExample) |
| TW (2) | TW202334125A (enExample) |
| WO (1) | WO2022058871A1 (enExample) |
| ZA (1) | ZA202303655B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114667147B (zh) | 2019-08-26 | 2024-09-06 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 |
| US20250041298A1 (en) * | 2021-12-02 | 2025-02-06 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| EP4561571A1 (en) | 2022-07-29 | 2025-06-04 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| US12338248B2 (en) | 2023-07-21 | 2025-06-24 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207463A1 (en) * | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| KR102587758B1 (ko) * | 2016-07-13 | 2023-10-12 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
| RS61934B1 (sr) | 2016-08-15 | 2021-07-30 | Pfizer | Inhibitori piridopirimdinona cdk2/ 4/6 |
-
2021
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207463A1 (en) * | 2018-04-26 | 2019-10-31 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116507620A (zh) | 2023-07-28 |
| SI4214202T1 (sl) | 2025-05-30 |
| EP4214202A1 (en) | 2023-07-26 |
| HUE070846T2 (hu) | 2025-07-28 |
| PL4214202T3 (pl) | 2025-05-19 |
| TW202216698A (zh) | 2022-05-01 |
| MX2023003054A (es) | 2023-04-05 |
| TWI809503B (zh) | 2023-07-21 |
| CA3195063A1 (en) | 2022-03-24 |
| JP7291839B2 (ja) | 2023-06-15 |
| DK4214202T3 (da) | 2025-03-31 |
| JP7260606B2 (ja) | 2023-04-18 |
| TW202334125A (zh) | 2023-09-01 |
| EP4214202B1 (en) | 2025-02-26 |
| AU2021345531A1 (en) | 2023-04-20 |
| JP2022186995A (ja) | 2022-12-15 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4578450A2 (en) | 2025-07-02 |
| BR112023004713A2 (pt) | 2023-04-18 |
| JP2022049005A (ja) | 2022-03-28 |
| KR20230069983A (ko) | 2023-05-19 |
| PT4214202T (pt) | 2025-04-11 |
| ES3022913T3 (en) | 2025-05-29 |
| CN116507620B (zh) | 2025-11-18 |
| ZA202303655B (en) | 2024-09-25 |
| WO2022058871A1 (en) | 2022-03-24 |
| FI4214202T3 (fi) | 2025-04-25 |
| EP4578450A3 (en) | 2025-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021345531B2 (en) | Solid forms of a CDK4 inhibitor | |
| AU2021404974B2 (en) | Solid forms of a cdk2 inhibitor | |
| US12030873B2 (en) | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | |
| KR20230121756A (ko) | Fgfr 억제제 및 이의 제조 및 사용 방법 | |
| US20220056011A1 (en) | Crystalline forms of a quinazoline compound and its hydrochloride salts | |
| RU2850825C1 (ru) | Твердые формы ингибитора cdk2 | |
| JP2025540560A (ja) | Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩 | |
| BR112023004713B1 (pt) | Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica | |
| HK40087859A (zh) | Cdk4抑制剂的固体形式 | |
| HK40125945A (zh) | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 | |
| BR112019019948B1 (pt) | Forma cristalina de derivado de 6-pirimidina-isoindol, seu processo de produção, sal amorfo, composição farmacêutica, e seus usos para fabricação de um medicamento | |
| HK40023945B (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| HK40023945A (en) | 6-pyrimidin-isoindole derivative as erk1/2 inhibitor | |
| HK1233924B (en) | Derivatives of cephalosporin for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |